Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

SEC Form 10-K: For the fiscal year ended December 31, 2024

BPTH_Form_10-K_20250327

SEC Form 8-K: Press Release dated March 18, 2025

BPTH_20250318_8-K

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_20250307

SEC Form 8-K

BPTH_20250217_8-K

SEC Form S-1/A

BPTH._S-1_A _20250212

SEC Form S-1

BPTH_S-1_20250121

SEC Form 8-K: Press Release dated January10, 2025

BPTH_20250110_8-K

SEC Form 8-K: Press Release dated December 19, 2024

BPTH_20241219_8-K

SEC Form 8-K: Other Items

BPTH_24-31094-1_D1.2_20241213Download

SEC Form 8-K: Press Release dated December 11, 2024

BPTH_20241212_8-K

Bio-Path Holdings

All Rights Reserved

Office:

625 Stanwix Street
Pittsburgh, PA, 15222

T: (630) 708-0750

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us